285 related articles for article (PubMed ID: 18657103)
1. The costs of care in atrial fibrillation and the effect of treatment modalities in Germany.
McBride D; Mattenklotz AM; Willich SN; Brüggenjürgen B
Value Health; 2009; 12(2):293-301. PubMed ID: 18657103
[TBL] [Abstract][Full Text] [Related]
2. [Atrial fibrillation in Germany: A prospective cost of illness study].
Spyra A; Daniel D; Thate-Waschke IM; Berghaus S; Willich S; Zeymer U; Rychlik R
Dtsch Med Wochenschr; 2015 Jul; 140(14):e142-8. PubMed ID: 26182263
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of practice patterns in the treatment of atrial fibrillation among the commercially insured.
Liu J; Sylwestrzak G; Barron J; Rosenberg A; White J; Whitney J; Redberg R; Malenka D
Curr Med Res Opin; 2014 Sep; 30(9):1707-13. PubMed ID: 24809834
[TBL] [Abstract][Full Text] [Related]
4. Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategies.
Poulin F; Khairy P; Roy D; Levesque S; Talajic M; Guertin JR; Lelorier J;
Can J Cardiol; 2013 Oct; 29(10):1256-62. PubMed ID: 23751149
[TBL] [Abstract][Full Text] [Related]
5. Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France.
Cotté FE; Chaize G; Kachaner I; Gaudin AF; Vainchtock A; Durand-Zaleski I
J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):e73-83. PubMed ID: 24119623
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation.
Catherwood E; Fitzpatrick WD; Greenberg ML; Holzberger PT; Malenka DJ; Gerling BR; Birkmeyer JD
Ann Intern Med; 1999 Apr; 130(8):625-36. PubMed ID: 10215558
[TBL] [Abstract][Full Text] [Related]
7. Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] study).
Zoni-Berisso M; Filippi A; Landolina M; Brignoli O; D'Ambrosio G; Maglia G; Grimaldi M; Ermini G
Am J Cardiol; 2013 Mar; 111(5):705-11. PubMed ID: 23273528
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of radiofrequency catheter ablation as first-line treatment for paroxysmal atrial fibrillation: results from a MANTRA-PAF substudy.
Aronsson M; Walfridsson H; Janzon M; Walfridsson U; Nielsen JC; Hansen PS; Johannessen A; Raatikainen P; Hindricks G; Kongstad O; Pehrson S; Englund A; Hartikainen J; Mortensen LS; Levin LÅ
Europace; 2015 Jan; 17(1):48-55. PubMed ID: 25341739
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of rhythm versus rate control in atrial fibrillation.
Marshall DA; Levy AR; Vidaillet H; Fenwick E; Slee A; Blackhouse G; Greene HL; Wyse DG; Nichol G; O'Brien BJ;
Ann Intern Med; 2004 Nov; 141(9):653-61. PubMed ID: 15520421
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
Hohnloser SH; Cappato R; Ezekowitz MD; Evers T; Sahin K; Kirchhof P; Meng IL; van Eickels M; Camm AJ;
Europace; 2016 Feb; 18(2):184-90. PubMed ID: 26487668
[TBL] [Abstract][Full Text] [Related]
11. Resource utilization and outcomes in patients with atrial fibrillation: a case control study.
Boggon R; Lip GY; Gallagher AM; van Staa TP
Appl Health Econ Health Policy; 2012 Jul; 10(4):249-59. PubMed ID: 22540235
[TBL] [Abstract][Full Text] [Related]
12. Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation--results from the RAte Control versus Electrical cardioversion (RACE) study.
Hagens VE; Vermeulen KM; TenVergert EM; Van Veldhuisen DJ; Bosker HA; Kamp O; Kingma JH; Tijssen JG; Crijns HJ; Van Gelder IC;
Eur Heart J; 2004 Sep; 25(17):1542-9. PubMed ID: 15342174
[TBL] [Abstract][Full Text] [Related]
13. Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital.
Allen Lapointe NM; Sun JL; Kaplan S; d'Almada P; Al-Khatib SM
Am J Cardiol; 2008 Apr; 101(8):1134-41. PubMed ID: 18394447
[TBL] [Abstract][Full Text] [Related]
14. Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors.
Amin AN; Jhaveri M; Lin J
Adv Ther; 2011 Oct; 28(10):907-26. PubMed ID: 21971681
[TBL] [Abstract][Full Text] [Related]
15. Rhythm control versus rate control in patients with persistent atrial fibrillation. Results of the HOT CAFE Polish Study.
Opolski G; Torbicki A; Kosior D; Szulc M; Zawadzka M; Pierścińska M; Kołodziej P; Stopiński M; Wozakowska-Kapłon B; Achremczyk P; Rabczenko D
Kardiol Pol; 2003 Jul; 59(7):1-16; discussion 15-16. PubMed ID: 14560344
[TBL] [Abstract][Full Text] [Related]
16. Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy.
Kim MH; Lin J; Hussein M; Battleman D
Curr Med Res Opin; 2009 Dec; 25(12):3037-47. PubMed ID: 19852699
[TBL] [Abstract][Full Text] [Related]
17. Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation.
Kim MH; Klingman D; Lin J; Pathak P; Battleman DS
Ann Pharmacother; 2009 May; 43(5):840-8. PubMed ID: 19417111
[TBL] [Abstract][Full Text] [Related]
18. [Atrial fibrillation--epidemiologic, economic and individual burden of disease].
Brüggenjürgen B; Reinhold T; McBride D; Willich SN
Dtsch Med Wochenschr; 2010 Mar; 135 Suppl 2():S21-5. PubMed ID: 20221974
[TBL] [Abstract][Full Text] [Related]
19. The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study.
Brüggenjürgen B; Rossnagel K; Roll S; Andersson FL; Selim D; Müller-Nordhorn J; Nolte CH; Jungehülsing GJ; Villringer A; Willich SN
Value Health; 2007; 10(2):137-43. PubMed ID: 17391422
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation.
Eckman MH; Falk RH; Pauker SG
Arch Intern Med; 1998 Aug 10-24; 158(15):1669-77. PubMed ID: 9701102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
